Affiliations: [a] Department of Respiratory Medicine, First Affiliated Hospital, Xi'an Medical University, Xi'an 710077, Shaanxi, China | [b] Department of Respiratory Medicine, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China | [c] Department of Respiratory Medicine, Gansu Provincial Hospital, Lanzhou, Gansu, China | [d] Institute of Epidemiology and Health Statistics, School of Public Health, Lanzhou University, Lanzhou, Gansu, China
Correspondence:
[*]
Corresponding author: Biaoxue Rong, Department of Respiratory Medicine, First Affiliated Hospital, Xi'an Medical University, 48 Fenghao West Road, Xi'an 710077, Shaanxi, China. Tel.: +86 029 8767 9300; E-mail:[email protected]
Abstract: BACKGROUND: Previous studies show that overexpression of stathmin
involved in the malignant biological behavior of lung cancer. This
investigation is to disclose the expression status of stathmin in non-small
cell lung cancer (NSCLC) and its clinical value for the diagnosis and
prognosis to lung cancer. METHODS: The expression of stathmin in cells and tissues of NSCLC
was examined using immunohistochemistry (IHC), in-situ hybridization (ISH), and
Western blot. The correlation between stathmin expression and
survival of lung cancer patients was evaluated by a Kaplan-Meier method
and the multiple regression analysis. RESULTS: NSCLC tissues and cells showed an overexpression of
stathmin compared with normal lung tissues and cells (p< 0.05). And the
expression level of stathmin was significantly associated with lung
adenocarcinoma (LAC) (p< 0.05), lymphatic invasion (p< 0.05) and advanced
stages of NSCLC (p< 0.05). Moreover, overexpression of stathmin predicted a
reduced survival (p<0.05). CONCLUSION: Increased stathmin correlated with pathologic grade,
lymphatic invasion, advanced stage and poor survival of NSCLC, which
indicated that stathmin could serve as a potential biomarker of NSCLC.
